Targeting neoantigens in multiple myeloma by TCR-transgenic T cells (A03)

• Subject Area: Hematology, Oncology ; Immunology
• Term: since 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 452881907

Specific targeting of neoantigens by vaccines or transfer of T-cell receptor (TCR)- transgenic T cells may represent an attractive treatment strategy in myeloma. We will take advantage of previously isolated neoantigen-specific TCR and challenge their function in the myleoma context. T cells modified by neoantigen-specific TCR will be compared with myeloma-specific chimeric antigen receptors (CAR) focusing especially on the role of antigen sensing as well as the impact of disease-specific therapeutics in combinatorial approaches. For subsequent translational purposes, novel TCR with reactivity against myeloma-derived neoantigens will be simultaneously isolated and characterized.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 338: LETSIMMUN - Lymphocyte Engineering for Therapeutic Synthetic Immunity
• Applicant Institution: Technische Universität München (TUM)
• Project Head: Professorin Dr. Angela Krackhardt